Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival

Sikiru A. Tinubu, John Hakimi, Jo A. Kondas, Pascal Bailon, Philip C. Familletti, Cheryl Spence, Michael D. Crittenden, Gary L. Parenteau, Fredrick M. Dirbas, Mitsuro Tsudo, John D. Bacher, Claude Sportes, Jean L. Martinucci, Carolyn K. Goldman, Richard E. Clark, Thomas A. Waldmann

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

IL-2Rs are expressed by T cells activated in response to foreign histocompatibility Ags but not by normal cells. This difference in IL-2R expression is exploited by blockade of IL-2Rs to achieve immunosuppression. High affinity IL-2Rs involve three subunits, IL-2Rα, IL-2Rβ, and IL-2Rγ. Murine Mikβ1, a mAb that blocks IL-2 binding to IL-2Rβ, was developed as an immunosuppressive agent. There was modest prolongation of cynomolgus cardiac allograft survival in animals treated with murine Mikβ1 (mean survival 11.8 ± 1.6 days compared with 8.2 ± 0.4 days in untreated animals; p = 0.06). However, murine Mikβ1 is ineffective in recruiting primate effector cells and is neutralized by monkey Abs directed toward the infused Ab. To circumvent these limitations, a humanized form of Mikβ1, which is a largely human IgG1k Ab, except that murine hypervariable regions are retained, was developed. In vivo plasma survival of humanized Mikβ1 was threefold longer than simultaneously administered murine Mikβ1 (terminal t( 1/2 ), 104 ± 10 h vs 37 ± 2 h). Furthermore, humanized Mikβ1 manifests Ab-dependent cellular cytotoxicity, an activity that is absent with the parental murine Mikβ1. Graft survival was significantly prolonged by humanized Mikβ1 treatment with survivals of 22, 22, 24, 27, 44, and >300 days (p vs control <0.01; p vs murine Mikβ1 <0.01). Survival was not prolonged further (p > 0.3) by the addition of humanized anti-Tac, which blocks interaction of IL-2 with IL- 2Rα subunits. There was no toxicity attributable to the use of Mikβ1 Abs. Thus, humanized Mikβ1 prolonged cardiac allograft survival in primates without toxicity and may be effective as an adjunct to standard immunosuppressive therapy.

Original languageEnglish (US)
Pages (from-to)4330-4338
Number of pages9
JournalJournal of Immunology
Volume153
Issue number9
StatePublished - Nov 1 1994

Fingerprint

Antibodies, Monoclonal, Humanized
Interleukin-2 Receptors
Immunosuppressive Agents
Primates
Interleukin-2
Allografts
Histocompatibility
Survival
Graft Survival
Immunosuppression
Haplorhini
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Tinubu, S. A., Hakimi, J., Kondas, J. A., Bailon, P., Familletti, P. C., Spence, C., ... Waldmann, T. A. (1994). Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival. Journal of Immunology, 153(9), 4330-4338.

Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival. / Tinubu, Sikiru A.; Hakimi, John; Kondas, Jo A.; Bailon, Pascal; Familletti, Philip C.; Spence, Cheryl; Crittenden, Michael D.; Parenteau, Gary L.; Dirbas, Fredrick M.; Tsudo, Mitsuro; Bacher, John D.; Sportes, Claude; Martinucci, Jean L.; Goldman, Carolyn K.; Clark, Richard E.; Waldmann, Thomas A.

In: Journal of Immunology, Vol. 153, No. 9, 01.11.1994, p. 4330-4338.

Research output: Contribution to journalArticle

Tinubu, SA, Hakimi, J, Kondas, JA, Bailon, P, Familletti, PC, Spence, C, Crittenden, MD, Parenteau, GL, Dirbas, FM, Tsudo, M, Bacher, JD, Sportes, C, Martinucci, JL, Goldman, CK, Clark, RE & Waldmann, TA 1994, 'Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival', Journal of Immunology, vol. 153, no. 9, pp. 4330-4338.
Tinubu SA, Hakimi J, Kondas JA, Bailon P, Familletti PC, Spence C et al. Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival. Journal of Immunology. 1994 Nov 1;153(9):4330-4338.
Tinubu, Sikiru A. ; Hakimi, John ; Kondas, Jo A. ; Bailon, Pascal ; Familletti, Philip C. ; Spence, Cheryl ; Crittenden, Michael D. ; Parenteau, Gary L. ; Dirbas, Fredrick M. ; Tsudo, Mitsuro ; Bacher, John D. ; Sportes, Claude ; Martinucci, Jean L. ; Goldman, Carolyn K. ; Clark, Richard E. ; Waldmann, Thomas A. / Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival. In: Journal of Immunology. 1994 ; Vol. 153, No. 9. pp. 4330-4338.
@article{2f48db546e5b49fb884b42dffda4bdd4,
title = "Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival",
abstract = "IL-2Rs are expressed by T cells activated in response to foreign histocompatibility Ags but not by normal cells. This difference in IL-2R expression is exploited by blockade of IL-2Rs to achieve immunosuppression. High affinity IL-2Rs involve three subunits, IL-2Rα, IL-2Rβ, and IL-2Rγ. Murine Mikβ1, a mAb that blocks IL-2 binding to IL-2Rβ, was developed as an immunosuppressive agent. There was modest prolongation of cynomolgus cardiac allograft survival in animals treated with murine Mikβ1 (mean survival 11.8 ± 1.6 days compared with 8.2 ± 0.4 days in untreated animals; p = 0.06). However, murine Mikβ1 is ineffective in recruiting primate effector cells and is neutralized by monkey Abs directed toward the infused Ab. To circumvent these limitations, a humanized form of Mikβ1, which is a largely human IgG1k Ab, except that murine hypervariable regions are retained, was developed. In vivo plasma survival of humanized Mikβ1 was threefold longer than simultaneously administered murine Mikβ1 (terminal t( 1/2 ), 104 ± 10 h vs 37 ± 2 h). Furthermore, humanized Mikβ1 manifests Ab-dependent cellular cytotoxicity, an activity that is absent with the parental murine Mikβ1. Graft survival was significantly prolonged by humanized Mikβ1 treatment with survivals of 22, 22, 24, 27, 44, and >300 days (p vs control <0.01; p vs murine Mikβ1 <0.01). Survival was not prolonged further (p > 0.3) by the addition of humanized anti-Tac, which blocks interaction of IL-2 with IL- 2Rα subunits. There was no toxicity attributable to the use of Mikβ1 Abs. Thus, humanized Mikβ1 prolonged cardiac allograft survival in primates without toxicity and may be effective as an adjunct to standard immunosuppressive therapy.",
author = "Tinubu, {Sikiru A.} and John Hakimi and Kondas, {Jo A.} and Pascal Bailon and Familletti, {Philip C.} and Cheryl Spence and Crittenden, {Michael D.} and Parenteau, {Gary L.} and Dirbas, {Fredrick M.} and Mitsuro Tsudo and Bacher, {John D.} and Claude Sportes and Martinucci, {Jean L.} and Goldman, {Carolyn K.} and Clark, {Richard E.} and Waldmann, {Thomas A.}",
year = "1994",
month = "11",
day = "1",
language = "English (US)",
volume = "153",
pages = "4330--4338",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "9",

}

TY - JOUR

T1 - Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival

AU - Tinubu, Sikiru A.

AU - Hakimi, John

AU - Kondas, Jo A.

AU - Bailon, Pascal

AU - Familletti, Philip C.

AU - Spence, Cheryl

AU - Crittenden, Michael D.

AU - Parenteau, Gary L.

AU - Dirbas, Fredrick M.

AU - Tsudo, Mitsuro

AU - Bacher, John D.

AU - Sportes, Claude

AU - Martinucci, Jean L.

AU - Goldman, Carolyn K.

AU - Clark, Richard E.

AU - Waldmann, Thomas A.

PY - 1994/11/1

Y1 - 1994/11/1

N2 - IL-2Rs are expressed by T cells activated in response to foreign histocompatibility Ags but not by normal cells. This difference in IL-2R expression is exploited by blockade of IL-2Rs to achieve immunosuppression. High affinity IL-2Rs involve three subunits, IL-2Rα, IL-2Rβ, and IL-2Rγ. Murine Mikβ1, a mAb that blocks IL-2 binding to IL-2Rβ, was developed as an immunosuppressive agent. There was modest prolongation of cynomolgus cardiac allograft survival in animals treated with murine Mikβ1 (mean survival 11.8 ± 1.6 days compared with 8.2 ± 0.4 days in untreated animals; p = 0.06). However, murine Mikβ1 is ineffective in recruiting primate effector cells and is neutralized by monkey Abs directed toward the infused Ab. To circumvent these limitations, a humanized form of Mikβ1, which is a largely human IgG1k Ab, except that murine hypervariable regions are retained, was developed. In vivo plasma survival of humanized Mikβ1 was threefold longer than simultaneously administered murine Mikβ1 (terminal t( 1/2 ), 104 ± 10 h vs 37 ± 2 h). Furthermore, humanized Mikβ1 manifests Ab-dependent cellular cytotoxicity, an activity that is absent with the parental murine Mikβ1. Graft survival was significantly prolonged by humanized Mikβ1 treatment with survivals of 22, 22, 24, 27, 44, and >300 days (p vs control <0.01; p vs murine Mikβ1 <0.01). Survival was not prolonged further (p > 0.3) by the addition of humanized anti-Tac, which blocks interaction of IL-2 with IL- 2Rα subunits. There was no toxicity attributable to the use of Mikβ1 Abs. Thus, humanized Mikβ1 prolonged cardiac allograft survival in primates without toxicity and may be effective as an adjunct to standard immunosuppressive therapy.

AB - IL-2Rs are expressed by T cells activated in response to foreign histocompatibility Ags but not by normal cells. This difference in IL-2R expression is exploited by blockade of IL-2Rs to achieve immunosuppression. High affinity IL-2Rs involve three subunits, IL-2Rα, IL-2Rβ, and IL-2Rγ. Murine Mikβ1, a mAb that blocks IL-2 binding to IL-2Rβ, was developed as an immunosuppressive agent. There was modest prolongation of cynomolgus cardiac allograft survival in animals treated with murine Mikβ1 (mean survival 11.8 ± 1.6 days compared with 8.2 ± 0.4 days in untreated animals; p = 0.06). However, murine Mikβ1 is ineffective in recruiting primate effector cells and is neutralized by monkey Abs directed toward the infused Ab. To circumvent these limitations, a humanized form of Mikβ1, which is a largely human IgG1k Ab, except that murine hypervariable regions are retained, was developed. In vivo plasma survival of humanized Mikβ1 was threefold longer than simultaneously administered murine Mikβ1 (terminal t( 1/2 ), 104 ± 10 h vs 37 ± 2 h). Furthermore, humanized Mikβ1 manifests Ab-dependent cellular cytotoxicity, an activity that is absent with the parental murine Mikβ1. Graft survival was significantly prolonged by humanized Mikβ1 treatment with survivals of 22, 22, 24, 27, 44, and >300 days (p vs control <0.01; p vs murine Mikβ1 <0.01). Survival was not prolonged further (p > 0.3) by the addition of humanized anti-Tac, which blocks interaction of IL-2 with IL- 2Rα subunits. There was no toxicity attributable to the use of Mikβ1 Abs. Thus, humanized Mikβ1 prolonged cardiac allograft survival in primates without toxicity and may be effective as an adjunct to standard immunosuppressive therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028138620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028138620&partnerID=8YFLogxK

M3 - Article

C2 - 7930631

AN - SCOPUS:0028138620

VL - 153

SP - 4330

EP - 4338

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 9

ER -